Cancer Research UK Biomolecular Structure Group, The School of Pharmacy, University of London, London, UK.
FEBS J. 2010 Mar;277(5):1118-25. doi: 10.1111/j.1742-4658.2009.07463.x. Epub 2009 Nov 27.
The 3'-ends of human chromosomal DNA terminate in short single-stranded guanine-rich tandem-repeat sequences. In cancer cells, these are associated with the telomere-maintenance enzyme telomerase together with the end-binding protein hPOT1. Small molecules that can compete with these proteins and induce the single-stranded DNA to form quadruplex-ligand complexes are, in effect, able to expose these 3'-ends, which results in the activation of a DNA damage response and selective inhibition of cell growth. Several of these G-quadruplex binding molecules have shown promising anticancer activity in tumour xenograft models, which indicate that the approach may be applicable to the treatment of a wide range of human cancers. This minireview summarizes the available data on these compounds and the challenges posed for drug discovery.
人类染色体 DNA 的 3'-末端终止于短的单链富含鸟嘌呤的串联重复序列。在癌细胞中,这些序列与端粒维持酶端粒酶以及末端结合蛋白 hPOT1 相关联。可以与这些蛋白竞争并诱导单链 DNA 形成四链体配体复合物的小分子,实际上能够暴露这些 3'-末端,从而激活 DNA 损伤反应并选择性抑制细胞生长。这些 G-四链体结合分子中的几种在肿瘤异种移植模型中表现出有希望的抗癌活性,这表明该方法可能适用于治疗广泛的人类癌症。这篇综述总结了这些化合物的现有数据以及药物发现所面临的挑战。